Clinical Trial Update: An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks [Phase 2]

View source ↗

Summary

A Phase 2 imaging study comparing rilapladib versus placebo in patients with atherosclerosis over 12 weeks has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• Rilapladib (rilapladib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 2 | Status: COMPLETED